Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
Lung-MAP Trial Will Test Five Investigational Approaches, Including Amgen’s Rilotumumab, an Investigational Fully Human Monoclonal Antibody THOUSAND OAKS, Calif., June 16, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) announced today that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung […]